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1. Introduction 
Opioid Maintenance Therapy (OMT) is an effective treatment for opioid addiction. In Australia 
the main forms of OMT are methadone and buprenorphine. OMT provides a regular, consistent 
and long-acting opioid dose that allows people the opportunity to regain control of their lives. 
A long-term OMT program enables individuals to improve their physical and mental health, 
resume employment and/or education and strengthen their relationships with family, friends 
and the wider community. It also greatly reduces people’s risk of fatal overdose, which kills 
more Australians each year than car accidents.  
Better access to OMT will help address growing rates of prescription opioid misuse and 
overdose. Under the present system, it is cheaper and easier to procure prescription opioids 
than OMT. Ensuring OMT is affordable is an important strategy to help stem prescription opioid 
as well as heroin addiction. 
This paper focuses on one major impediment to enabling more Australians to access 
medication-assisted treatment: the requirement that people on OMT pay a fee for each dose 
they receive, rather than a flat fee per script. These daily OMT fees are described in this paper 
as co-payments, and they are severely compromising the public health and community benefits 
of an exceptional form of drug addiction treatment. The effectiveness of OMT is dependent on 
people staying in treatment and co-payments are the main reason people drop out of treatment 
— often resuming illicit drug use and criminal activity. Crime related to drug misuse is 
estimated to cost $3, 161 million per year in Australia. 
Reform is needed to ensure better access to OMT. Co-payment relief must be provided to 
patients through the Pharmaceutical Benefits Scheme (PBS) to ensure a coordinated, national 
approach. This will increase patient retention and uptake of OMT across Australia, resulting in 
better individual outcomes for illicit opioid users and reduced drug-related health and crime 
costs to the community. 
2. Opioid use 
The illicit use of opioids such as heroin, and pharmaceutical opioids such as morphine and 
oxycodone, is a serious health and social problem. Opioid users are more likely to experience 
mental and physical health problems, social and economic disadvantage, and poorer levels of 
overall well-being (Ross, Teeson et al., 2005; Dietze, Stoové et al., 2010). People who inject 
these drugs are at high risk from blood borne viruses such as hepatitis C and HIV/AIDS 
(Mathers, Degenhardt et al., 2008; Nelson, Mathers et al., 2011) and are at increased risk of 
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mortality, primarily from overdose (Degenhardt, Bucello et al., 2010; Degenhardt, Whiteford et 
al., 2013; Pierce, Bird et al., 2015). 
Opioid addiction imposes a significant health and economic burden on the wider community, 
resulting in substantial costs to treatment and prevention services, as well as health care more 
generally (Collins & Lapsley, 2008; Ruetsch, 2010). Misuse of these drugs is associated with 
costs to the community, such as productivity loss in the workplace, organised and other crime, 
and social welfare expenditure (Hall, Doran et al., 2006; Ruetsch, 2010). There are also social 
costs associated with opioid addiction. These include poverty, family disruption, harm to the 
welfare of children, and contact with the justice and corrections system (Hall, Lynskey et al., 
1999; Horyniak, Higgs et al., 2013). 
Not all people who inject opioids are addicted to these drugs. Nor do they necessarily need or 
want treatment (Dean, Saunders et al., 2011). However, for those who do seek treatment, OMT 
is an effective strategy that enables them to reduce or cease their drug use (Mattick, Breen et 
al., 2009; Mattick, Breen et al., 2014). Ensuring that people who inject opioids have good access 
to quality OMT, benefits the individual and the wider community.  
3. What is Opioid Maintenance Therapy? 
OMT is the long-term provision of medication for the treatment of opioid addiction. There are 
two medications legally able to be used in Australia for OMT. These are methadone and 
buprenorphine (which is increasingly used as a naloxone combination called Suboxone®). A 
number of other countries have used other replacement medications for OMT, including heroin.  
These medications stimulate opioid receptors in the brain and, at optimised doses, ameliorate 
opioid withdrawal symptoms without causing intoxication. Methadone and buprenorphine are 
particularly effective because they are long acting and can be administered orally, reducing the 
risks of injecting. They may also block the effects of other opioids which can reduce the 
incentive to continue opioid abuse. Due to their effectiveness in addressing illicit opioid use, 
both methadone and buprenorphine are listed by the World Health Organisation (WHO) as 
essential medicines (WHO Expert Committee on the Selection and Use of Essential Medicines, 
2006).  
OMT medications are potent and can cause overdose and death if inappropriately used (Bell, 
Butler et al., 2009). Because of this, these medications are mostly dispensed in a supervised 
environment where people on OMT must consume their methadone or buprenorphine in full 
view of a pharmacist. This is the main way of controlling administration of these drugs in order 
to reduce the chances of misuse or diversion to the illicit market and risks to consumers and 
the wider community. Some OMT clients receive a number of ‘takeaway’ doses a week. These 
can be taken home and consumed without supervision. Takeaway doses are very important 
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because they provide clients with some degree of flexibility which can help with paid and 
unpaid work, education and training, and parenting (Fraser, Valentine et al., 2007).  
4. Effectiveness of OMT 
OMT is an effective treatment for opioid addiction improving the mental, physical and social 
health of patients (Gossop, Marsden et al., 2003; Maremmani, Pani et al., 2007; Lawrinson, Ali 
et al., 2008; Teesson, Mills et al., 2008). OMT patients substantially decrease their use of heroin 
and other opioids, reduce their risk of mortality and morbidity and reduce the transmission risks 
of injection-related disease such as HIV/AIDS and hepatitis, and are able to increase 
participation in employment, parenting and community responsibilities (Cornish, Macleod et al., 
2010; Grönbladh, Öhlund et al., 1990; Hser, Hoffman et al., 2001; Mattick, Breen et al., 2009; 
Mattick, Breen et al., 2014; Ritter & Chalmers, 2009; Teesson et al., 2008; Turner, Hutchinson et 
al., 2011; Ward, Mattick et al., 1998). 
Participation in OMT is associated with reduced involvement in property crime and non-violent 
forms of criminal activity as well as violent crime (Bukten, Skurtveit et al., 2012; Gossop, 
Trakada et al., 2005; Hall, 1996; Havenes et al., 2012; Teesson et al., 2008). 
By removing the drivers for much of the problematic behaviour associated with opioid 
addiction, OMT can provide people with an opportunity to make sustainable changes in their 
lives. In this way, OMT is an effective support to other therapeutic approaches (including 
withdrawal, counselling and rehabilitation) as it promotes the achievement of goals that are 
indicative of sustained change. For these reasons, it is a prime example of an addiction 
intervention that also enhances the prospects of long-term recovery. 
Access to, and retention in, OMT is essential to successful treatment. OMT is most effective 
when patients remain in treatment for at least 12 months (Ward et al., 1998). Most available 
evidence suggests the majority of people leaving treatment will resume drug use (Ward et al., 
1998; Winstock, Lintzeris et al., 2011). This research illustrates how important it is that issues 
such as co-payments do not impact on people’s ability to access and stay on OMT.  
5. Australian policy 
OMT is an important, evidence-based strategy in Australia’s overall response to drug use. 
Historically, the large-scale rollout of methadone maintenance, combined with other harm 
reduction interventions, has meant that the high prevalence of HIV/AIDS seen overseas has 
been avoided in Australia (Fitzgerald & Sewards, 2002; Mathers, Degenhardt et al., 2008).  
National policy on opioid pharmacotherapies is clear on the goal of OMT: 
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The broad goal of treatment for opioid dependence is to reduce the health, social and 
economic harms to individuals and the community arising from illicit opioid use 
(Intergovernmental Committee on Drugs, 2007). 
This policy outlines the objectives of treatment and is explicit that retention in OMT is integral 
to success:  
The objectives of pharmacotherapy are to: 
• bring to an end or significantly reduce an individual’s illicit opioid use 
• reduce the risk of overdose 
• reduce the transmission of blood borne diseases 
• improve general health and social functioning, including a reduction in crime 
These objectives are achieved by engaging and retaining people dependent on opioids in 
treatment (Intergovernmental Committee on Drugs, 2007). 
There is a relatively stable population of around 47,500 OMT patients in Australia (Australian 
Institute of Health and Welfare, 2013a). This number has increased by less than 1% per year 
since 2010 after a period of rapid growth since 1998 (Australian Institute of Health and 
Welfare, 2013a). Yet, while a sizable number of people access this treatment, they face ongoing 
issues that can jeopardise the effectiveness of OMT. Of these issues, co-payments stand out as 
a problem that should be dealt with to ensure better outcomes (Kellsal, King et al., 2014). 
Addressing this issue is paramount if people using illicit opioids and the wider Australian 
community are to gain maximum benefit from the medical treatment of addiction.  
6. Models of OMT provision in Australia 
OMT is provided in four main ways in Australia. These are: 
• State and territory-funded specialist clinics. These are services for clients with 
extremely high needs. Specialist clinics provide adjunct services such as case 
management. OMT is provided at very low or no cost to the patient.  
• Community-based services. These include community pharmacists and General 
Practitioners (GPs). These services are intended to provide services for ‘stable’ OMT 
patients. Adjunct services in this model are not necessarily provided. Patients pay 
anywhere from $1 to $10 per day for OMT. 
• Private services. These are mostly found in New South Wales. Similar to community-
based provision they do not provide adjunct services. They are sometimes more 
expensive at around $10 per day to the patient. 
• Correctional-based services. OMT is provided in most states to inmates at no cost. 
Depending on the jurisdiction, people may continue their OMT program or begin OMT 
once incarcerated (Australian Institute of Health and Welfare, 2013a; Ritter & Chalmers, 
2009; Ritter & Lintzeris, 2004). 
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Australian jurisdictions have enlisted the support of generalist health providers such as GPs and 
pharmacists to provide the great bulk of OMT. In 2013, 82% of OMT prescribers were in private 
practice and 88% of dosing points were in community pharmacies (Australian Institute of 
Health and Welfare, 2013a). This model of provision requires patients to register with an 
authorised GP to prescribe their medication, and with a single pharmacy to provide supervised 
doses and takeaway doses. The pharmacist’s role includes monitoring the patient’s ongoing 
condition and alerting the prescriber of any problems.  
The benefits of delivering OMT through community services rather than specialist treatment 
centres (or private clinics) are argued to be: 
• an increase in the availability and accessibility of treatment including in regional and 
rural areas 
• the normalisation of drug treatment as a general health concern 
• that consumers feel less stigmatised attending a primary health care setting rather 
than a specialist program for treatment 
• savings to state government expenditure as the cost shifts to patients and the 
Australian government (Lintzeris, Koutroulis et al., 1996; Ritter & Chalmers, 2007; 
Treloar, Fraser et al., 2007; Winstock, Lea et al., 2010) 
The last point is an important one, as the cost-effectiveness of the community-based OMT 
model has allowed its expansion in order to respond to the demand for treatment. Yet, while 
the cost to government is low compared to other forms of drug treatment (Doran, 2007), OMT 
patients must carry the costs to pharmacists through program fees. Pharmacies are commercial 
enterprises. For these businesses to continue to provide OMT, it must remain financially viable.  
7. What are OMT co-payments? 
OMT co-payments are an ongoing issue for both OMT patients and their pharmacists (Fraser et 
al., 2007; Ritter & Chalmers, 2007; Shepard, Perrella et al., 2014). While consumers are usually 
bulkbilled through Medicare for visits to their GP, they are charged a program/dispensing fee by 
their pharmacist. This co-payment varies, and can range from $1 to $10 daily, but has remained 
relatively stable for the past twenty years. For example, an OMT patient’s co-payment per dose 
might be $5, regardless of whether or not the person has takeaway doses (hence making fewer 
visits to pharmacy) or attends the pharmacy each day. The weekly co-payment cost to patients 
paying $5 per day would typically be $35, whether they received takeaways or not.  
Pharmacists in most states receive no other payment for the provision of OMT, although there 
is a subsidy scheme in Tasmania and the Australian Capital Territory and an inducement 
scheme in New South Wales. Evidence suggests that consumer co-payments do not cover the 
costs of OMT provision (Feyer et al., 2008). However, co-payments have remained relatively 
stable, presumably because of the struggle consumers have paying these fees.  
OMT co-payments are charged to incorporate: 
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• the pharmacist’s time (they are required to prepare and provide the consumer’s dose, 
and complete all paper work) 
• consumables (cups, bottles, labels and cordial in some states) 
• general business costs 
Fees tend to be higher when OMT is provided through private clinics (mostly NSW) where OMT 
is their sole business.  
Public clinics might also charge dispensing fees, however, these are heavily or completely 
subsidised by the relevant state/territory government. These clinics tend to only treat patients 
for a limited time before they are referred to a GP and community pharmacy. Some patients 
may remain at these clinics for longer if they are considered unstable or complex to a degree 
that would make attending a community pharmacy an unviable option. Public clinics invariably 
have long waiting lists and usually equate the stability required for takeaway doses with the 
stability to dose at a pharmacy. Thus, while being affordable, public clinics provide very limited 
flexibility to people, impacting on their ability to gain employment, undertake study and 
engage in other meaningful activities. 
There is some argument that the time involved in supervised dispensing should be reflected in 
co-payments (Winstock et al., 2007). For instance, people on Suboxone® may be entitled to a 
greater number of takeaway doses, but they are not usually charged less (Winstock et al., 2007). 
However, as outlined above, program fees are not solely related to the cost of supervised 
dosing. Paperwork for OMT is similar, regardless of the way the medication is provided. 
Additionally, providing Suboxone® at a cheaper rate does not address the issue of co-payments 
in an equitable and sustainable way. It may also make the decision between buprenorphine and 
methadone financially driven, rather than determined on the basis of what is best for the 
individual patient.  
8. The impact of OMT co-payments 
The impact of OMT co-payments on patients is profound, potentially jeopardising treatment 
continuity and their therapeutic relationship with their pharmacists. The cost of treatment is 
critical to patient satisfaction and retention in the program (Booth, Corsi et al., 2004; Winstock 
et al., 2007; Lintzeris et al., 1996).  According to reports from advice and dispute resolution 
services for OMT patients, payment issues related to co-payments are the most common issue 
of concern, with up to 80% of patients contacting services for this reason (Rossmanith, 2011).  
Research with 120 OMT patients in Victoria (Rowe, 2008) found that many faced hardship with 
fees and this led to adverse outcomes. Some of the key findings of the report were that:  
• people on OMT often prioritise the payment of dispensing fees over basic necessities, 
including food and accommodation 
• OMT patients on low incomes are compelled to rely on emergency relief services to 
meet food and accommodation needs 
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• a significant minority of consumers engage in crime to meet co-payments 
• co-payments often contribute to a deterioration in the relationship between 
dispensing pharmacist and patient 
• the accumulation of debt through the inability to pay dispensing fees is a primary 
reason for the involuntary discontinuance of treatment 
• co-payments are the single greatest obstacle to retention in OMT 
• the withholding of OMT encourages illicit heroin and/or other opioid use 
• involuntary discontinuance of treatment is invariably followed by a return to 
problematic heroin use (Rowe, 2008, p.1) 
This body of evidence clearly shows the detrimental impact that OMT co-payments have on 
consumers and how these fees can contribute to the experience of economic hardship and 
continuing engagement in criminal activity.  
Co-payments also have a significant impact on pharmacies and their provision of OMT. A study 
with 669 pharmacies in New South Wales and Victoria found that only a third of pharmacies 
reported all clients were up to date with their co-payments (Winstock et al., 2010). It has been 
suggested that these fees impact on the willingness of pharmacists to provide OMT. That is, if 
clients were not struggling to pay fees, more pharmacists would be attracted to the program, 
thus providing better coverage of this much-needed form of treatment (Feyer et al., 2008). 
9. Budgeting on OMT 
As noted previously, OMT co-payments vary. Generally, however, these fees are around $30.00 
to $40.00 per week, but can be as much as $70 per week. Most OMT consumers are on low 
incomes, with many are in receipt of government benefits such as the Disability Support 
Pension (DSP) or Newstart (Chalmers & Ritter, 2012; Rowe, 2008). The maximum amount a 
single person can receive on DSP is $782.20 per fortnight, dropping to $589.60 each or 
$1,179.20 combined for couples on DSP. Newstart is $519.20 per fortnight. This drops to 
$468.80 per couple per fortnight if individuals are partnered with another Newstart recipient. 
Once $70.00 for two weeks of program fees is taken into account, the DSP reduces to $712.20 
per fortnight and Newstart reduces to $449.20. Program fees are about 9% of a single person’s 
total income on the DSP and 13% of their income on Newstart. Research shows that people 
living on benefits such as DSP and Newstart are struggling to afford the basics such as rent and 
food (Australian Council of Social Services, 2012). If people have children there are far higher 
additional costs.  
By requiring OMT consumers to pay daily dispensing fees to access their medication, we are 
adding to the extreme financial stress they already experience. This stress is counterproductive 
to the goals and benefits of OMT, including being able to parent and being an active member 
of the community. By keeping OMT consumers in a poverty trap we also increase their 
marginalisation. People on OMT face stigmatisation because of their drug use, and poverty adds 
to this stigma (Fraser et al., 2007).   
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Despite the known public health benefits of OMT, there is no systematic financial support for 
OMT patients experiencing difficulty paying for their medication. This places them in a unique 
position.  
Other Australian health consumers who receive medication for chronic and/or lifestyle related 
illnesses such as diabetes, smoking-related illness and hypercholesterolemia are not required 
to pay for their medication to be dispensed (Shepard et al., 2014). Nor are recipients of opioid 
medication such as Oxycontin® and MS Contin®. Whereas a person receiving a month’s dosage 
of prednisolone (an oral steroid for smoking-related illness) may pay less than $6 if they have a 
Health Care Card (HCC), OMT patients may pay more than $150 for a month’s provision of 
medication. 
The business costs of dispensing OMT are argued to be greater than the cost of dispensing 
medications for other chronic conditions, yet the fact remains that, unlike other patients, 
people on OMT pay a very high cost for their medication. This situation is discriminatory and 
inequitable.  
10. OMT and pharmaceutical opioids 
The misuse of pharmaceutical opioids is a growing problem in Australia and is associated with 
severe harms such as addiction and overdose (Australian Health and Welfare Institute, 2013b; 
Roxburgh, Ritter, Slade, & Burns, 2014). Better access to OMT could address the misuse of 
these drugs. . The cost of oxycodone can be as low as $6 a month, and a person receiving such 
opioid pharmaceuticals do not have to attend a pharmacy each day. On the other hand, OMT 
dispensing fees are around 25 times more expensive than prescription opioids. These cost 
inequities make it difficult to move people who are abusing drugs such as MS Contin® and 
Oxycontin® onto a treatment program. Yet, people on a supervised regime of OMT will achieve 
better outcomes than those receiving opioid medications in unsupervised circumstances where 
these drugs may be traded, trafficked and injected. 
Increasing numbers of pharmaceutically-dependent people are being treated by OMT 
(Australian Institute of Health and Welfare, 2013a; Ritter & Chalmers, 2009). Early research 
finds that OMT is a promising treatment for opioid pharmaceutical dependence, with most 
people appearing to successfully stabilise in treatment (Nielsen, Muhleisen et al., 2013).  
11. Cost-benefit to subsidising OMT co-payments 
With increasing health care costs and limited resources, government and policy makers require 
cost-effective solutions to issues such as opioid addiction. Shifting the cost of OMT dispensing 
to consumers through co-payments appears to reduce cost to government. However, if people 
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cannot stay on OMT because of these fees, there are far greater costs to the community (Collins 
& Lapsley, 2008). 
It makes economic sense for government to address the issue of OMT co-payments. Australian 
researchers developed a system dynamics model of OMT to explore some of the key issues of 
concern, including affordability (Chalmers & Ritter, 2012). The resulting modelling found that 
the overall cost for the provision of OMT is almost $11.73 million per month. Of this total, 43% 
is borne by state and territory governments, 33% by patients, and the remaining 24% by the 
Australian Government.  
The cost to the community related to untreated heroin use for the same period of time was 
estimated to be between $15.8 million and $31.6 million per month, significantly higher than 
$11.73 million. The ‘cost burden’ of ongoing heroin use includes:  
• health care costs (blood borne viruses, accidents, trauma, overdose) 
• crime (associated with heroin) 
• family disruption, domestic violence, impact on children 
It should be noted that this research did not examine the cost of untreated opioid 
pharmaceutical addiction. Based on their heroin-only data, the researchers concluded that if the 
Australian Government was to pay all program fees (estimated at around $4 million per month) 
this cost would be outweighed by the economic benefits accruing to the community through 
social and health benefits, such as reductions in health care utilisation and crime (Chalmers & 
Ritter, 2012). The researchers also take into account that, if OMT co-payments were subsidised, 
increasing people would take up OMT. Thus, with increasing numbers of OMT patients, the 
total of a full fee subsidy would increase yearly government expenditure by $81.8 million to 
$175.8 million (Chalmers & Ritter, 2012). 
12. Evidence for providing OMT co-payment relief 
There is strong evidence that providing OMT co-payment relief to patients will improve 
program continuity and their relationship with their pharmacist, with a number of studies 
evaluating fee-subsidy models.  
Australian research found that affordability had an impact on treatment by comparing a 
subsidised group of patients (at a flat rate of $15 per week) to an unsubsidised group (Feyer et 
al., 2008). Higher cost was associated with significantly poorer adherence to treatment. Other 
key findings were that: 
• affordability was a significant determinant of treatment outcome. A subsidised 
arrangement as part of a national funding model may lead to better compliance and 
treatment outcomes 
• any patient subsidy would need to take into account the real financial impact given 
the variability of co-payments 
• there is a case for means testing of a co-payment subsidy 
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• co-payments greater than $29.80 are associated with increased risk of being unable 
to maintain treatment (Feyer et al., 2008) 
This study also investigated the option of directly subsidising pharmacies. It was recommended 
that incentives be provided to pharmacies to improve their satisfaction and maintain their 
involvement in the program, as well as to attract new pharmacists.  
Another Australian study trialled three different models of dispensing fee assistance 
(Healthcare Management Advisors, 2007). These models were two partial OMT co-payment 
subsidies and a full co-payment subsidy. The findings of this research included that: 
• OMT patients and pharmacists reported being satisfied with the trial funding models 
• there were no statistically significant differences in satisfaction between the three 
funding models 
• pharmacists reported that the funding models trialled had a strong positive impact on 
service delivery. This was mainly related to improved relationships with patients due 
to reduced concerns about money and chasing of bad debts  
• OMT patients expressed satisfaction with the trial arrangements, with 91.4% stating 
that treatment arrangements were better during the trial than before (Healthcare 
Management Advisors, 2007) 
More recently, an Australian study found that the main reason people dropped out of OMT was 
the cost of co-payments. People in this study reported high levels of personal debt — an issue 
which is linked to adverse health outcomes (Shepard et al., 2014).  
The evidence shows that providing OMT co-payment assistance will enhance OMT outcomes. 
With co-payment subsidies, patients have better retention on OMT and a more productive 
relationship with their pharmacist. Further, if pharmacists do not have to deal with people 
struggling to pay fees they may be more likely to provide OMT, thus enhancing treatment 
coverage and accessibility. 
13. A cut-through solution to co-payments 
Medications such as methadone and buprenorphine are provided through the PBS. They are 
listed as ‘Section 100’ drugs, meaning that they are part of the ‘highly specialised drugs 
program’. To bring methadone and buprenorphine into line with other long-term medications, 
the conditions of their listing as a S100 must be changed to ensure that people on OMT are not 
paying uniquely high costs to receive their medication.  
We propose that methadone and buprenorphine (when used specifically for OMT) remain as 
S100 drugs, but with different provisions for supply. These new provisions would be to: 
• pay pharmacists a monthly fee per patient to cover the recording/dispensing fee, 
handling fee, counselling and pharmaceutical care 
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• require a monthly patient contribution. This would be $6.00 per months for those with a 
HCC and $36.90 for those without. This is in line with other PBS medications where the 
consumer pays a fee each time a prescription is filled  
To price this model we have assumed the value of providing buprenorphine is $9.47 per day 
and methadone is $11.51. These amounts are calculated from the PBS fee paid to pharmacists, 
as of September 2014, for dispensing a drug of addiction (other than OMT medication) (Newton, 
2014).  
MODEL SUMMARY 
Real cost of providing buprenorphine for one month1 at $9.47 per day   
 $284.10 
Real cost of providing methadone for one month at $11.51 per day    $345.30 
 
 
Cost of subsidising buprenorphine for one month: 
Co-payment subsidy less HCC patient contribution ($6.10)    $278.00 
Co-payment subsidy less non-HCC patient contribution ($37.70)   $246.40 
Cost of subsidising methadone for one month: 
Co-payment subsidy less HCC patient contribution ($6.10)    $339.20 
Co-payment subsidy less non-HCC patient contribution ($37.70)   $307.60 
Under this model patients pay, and OMT patients are charged $6.00 per month (if they are HCC 
holders) and $36.90 (if they are not HCC holders). The PBS, however, would subsidise HCC 
holders up to $339.30 per month and non-HCC holders $308.40 per month. The Medicare safety 
net would come into effect as it does with other health consumers.2  
Currently, there are around 37,471 people receiving OMT through pharmacies or private clinics 
with around two thirds (24,981) receiving methadone and the remaining one third (12,490) on 
buprenorphine.  
Based on current patient numbers this model would cost around $12 million per month, with 
methadone costing around $8.5 million and buprenorphine around $3.5 million. 
                                               
1 One month is 30 days as for most other PBS items. 
2 We have costed PBS co-payments in this model at the current rate. Rates are adjusted each year.  
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However, if this direct payment model were to be adopted, it would be reasonable to expect 
greater adherence and greater uptake of OMT treatment owing to the improvement in the 
program’s affordability. Hence, the total cost of subsidising co-payments would also increase.  
To put the cost of this proposal in perspective, consider the following typical scenario: 
A person suffering type 2 diabetes may be regularly prescribed some form of insulin. Lantus 
SoloStar® is one such form of insulin, provided to patients under the PBS scheme as a Schedule 
85 drug. The wholesale price of the drug is $408.30 per prescription (usually 5 flexpens), and 
the cost to the PBS is approximately $430.00 per prescription. Often, a person would require at 
least one prescription per month which, if they have a HCC, would cost them about $70.00 per 
year — and would cost the PBS more than $5000.00 per year. Overall, in 2010-2011 the cost to 
the PBS of Lantus SoloStar® amounted to more than $109 million.  
In comparison, a patient receiving OMT to treat and control their particular chronic disease is 
required to pay out more than $1500.00 per year as their patient contribution.  
The model outlined above is not the only option for addressing the issue of OMT co-payments. 
However, it is a potential cut-through solution that brings the provision of treatment to OMT 
clients in line with treatment for other chronic health care issues.  
14. Finding an equitable solution 
OMT is an especially cost-effective response to problematic opioid dependence. Other 
treatment options such as withdrawal, rapid detoxification or antagonist therapy are more 
expensive and have limited outcomes. OMT co-payments, however,  are an ongoing problem, 
compromising outcomes. OMT patients are often on low incomes and the high cost of 
treatment contributes to their poverty, making it hard for them to make positive changes in 
their lives.   
Almost all pharmacies are commercial enterprises. They should not be expected to provide a 
service without payment. OMT programs require considerable paperwork and, unlike other 
medications for chronic conditions, patients are required to be supervised when dosed. 
A subsidy scheme would reduce the financial burden on patients as well as make services more 
viable, therefore encouraging more providers to offer OMT. The costs of any subsidy scheme 
would be offset by a reduction in costs across the board for governments including justice and 
corrections, and health costs such as hospitals and mental health admissions. 
OMT is an effective treatment that provides benefits to individuals, their families and the wider 
community. People on OMT should be provided the same access to medication as other 
Australians with chronic health issues. 
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